186 related articles for article (PubMed ID: 36999577)
21. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
Benzaquen M
Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
[TBL] [Abstract][Full Text] [Related]
22. Treatment approaches of advanced cutaneous squamous cell carcinoma.
Peris K; Piccerillo A; Del Regno L; Di Stefani A
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():19-22. PubMed ID: 34855254
[TBL] [Abstract][Full Text] [Related]
23. Recent and Emerging Therapies for Cutaneous Squamous Cell Carcinomas of the Head and Neck.
Varra V; Smile TD; Geiger JL; Koyfman SA
Curr Treat Options Oncol; 2020 Apr; 21(5):37. PubMed ID: 32328817
[TBL] [Abstract][Full Text] [Related]
24. Stage IV cutaneous squamous cell carcinoma: treatment outcomes in a series of 42 patients.
Chapalain M; Baroudjian B; Dupont A; Lhote R; Lambert J; Bagot M; Lebbe C; Basset-Seguin N
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1202-1209. PubMed ID: 31587382
[TBL] [Abstract][Full Text] [Related]
25. Overview of guideline recommendations for the management of high-risk and advanced cutaneous squamous cell carcinoma.
Dessinioti C; Stratigos AJ
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():11-18. PubMed ID: 34855249
[TBL] [Abstract][Full Text] [Related]
26. Cutaneous Squamous Cell Carcinoma: Updates in Staging and Management.
Bander TS; Nehal KS; Lee EH
Dermatol Clin; 2019 Jul; 37(3):241-251. PubMed ID: 31084718
[TBL] [Abstract][Full Text] [Related]
27. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P
Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948
[TBL] [Abstract][Full Text] [Related]
28. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.
Migden MR; Chandra S; Rabinowits G; Chen CI; Desai J; Seluzhytsky A; Sasane M; Campanelli B; Chen Z; Freeman ML; Ibrahim SF; Khushalani NI; Andria M; Ruiz E
Future Oncol; 2020 Feb; 16(4):11-19. PubMed ID: 31951149
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous squamous cell carcinoma staging may influence management in users: A survey study.
Patel VA; McCullum C; Sparks AD; Schmults CD; Arron ST; Jambusaria-Pahlajani A
Cancer Med; 2022 Jan; 11(1):94-103. PubMed ID: 34796670
[TBL] [Abstract][Full Text] [Related]
30. Comparison of guidelines for the management of patients with high-risk and advanced cutaneous squamous cell carcinoma - a systematic review.
Heppt MV; Steeb T; Berking C; Nast A
J Eur Acad Dermatol Venereol; 2019 Dec; 33 Suppl 8():25-32. PubMed ID: 31833609
[TBL] [Abstract][Full Text] [Related]
31. [Cutaneous squamous cell carcinoma].
Leiter U; Gutzmer R; Alter M; Ulrich C; Lonsdorf AS; Sachse MM; Hillen U
Hautarzt; 2016 Nov; 67(11):857-866. PubMed ID: 27680009
[TBL] [Abstract][Full Text] [Related]
32. A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck.
Manyam BV; Garsa AA; Chin RI; Reddy CA; Gastman B; Thorstad W; Yom SS; Nussenbaum B; Wang SJ; Vidimos AT; Koyfman SA
Cancer; 2017 Jun; 123(11):2054-2060. PubMed ID: 28171708
[TBL] [Abstract][Full Text] [Related]
33. Guidelines of care for the management of cutaneous squamous cell carcinoma.
; ; Kim JYS; Kozlow JH; Mittal B; Moyer J; Olenecki T; Rodgers P
J Am Acad Dermatol; 2018 Mar; 78(3):560-578. PubMed ID: 29331386
[TBL] [Abstract][Full Text] [Related]
34. Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma.
Giri A; Bauman JR
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1029-1038. PubMed ID: 36106496
[TBL] [Abstract][Full Text] [Related]
35. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel.
Lebas E; Marchal N; Rorive A; Nikkels AF
Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680
[TBL] [Abstract][Full Text] [Related]
36. Advanced Cutaneous Squamous Cell Carcinoma Is Associated with Suboptimal Initial Management in a Cohort of 109 Patients.
Deilhes F; Boulinguez S; Pagès C; Paul C; Meyer N
Dermatology; 2019; 235(6):516-521. PubMed ID: 31387094
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant therapy for high-risk cutaneous squamous cell carcinoma: 10-year review.
Newman JG; Hall MA; Kurley SJ; Cook RW; Farberg AS; Geiger JL; Koyfman SA
Head Neck; 2021 Sep; 43(9):2822-2843. PubMed ID: 34096664
[TBL] [Abstract][Full Text] [Related]
38. Risk factors and timing of subsequent cutaneous squamous cell carcinoma in patients with cutaneous squamous cell carcinoma: A retrospective cohort study.
Rodriguez M; Beal BT; Manmohan M; Simmons E; Varra V; Xiong D; Eversman A; Briskin IN; Knackstedt T; Vidimos AT
J Am Acad Dermatol; 2021 Mar; 84(3):719-724. PubMed ID: 32861709
[TBL] [Abstract][Full Text] [Related]
39. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
Hernández-Guerrero T; Doger B; Moreno V
Drugs Today (Barc); 2019 Aug; 55(8):485-494. PubMed ID: 31461085
[TBL] [Abstract][Full Text] [Related]
40. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023.
Stratigos AJ; Garbe C; Dessinioti C; Lebbe C; van Akkooi A; Bataille V; Bastholt L; Dreno B; Dummer R; Fargnoli MC; Forsea AM; Harwood CA; Hauschild A; Hoeller C; Kandolf-Sekulovic L; Kaufmann R; Kelleners-Smeets NW; Lallas A; Leiter U; Malvehy J; Del Marmol V; Moreno-Ramirez D; Pellacani G; Peris K; Saiag P; Tagliaferri L; Trakatelli M; Ioannides D; Vieira R; Zalaudek I; Arenberger P; Eggermont AMM; Röcken M; Grob JJ; Lorigan P;
Eur J Cancer; 2023 Nov; 193():113252. PubMed ID: 37708630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
